AU2019414427A1 - Silencing TGF-beta 1 and Cox2 using siRNAs delivered in combination with immune checkpoint inhibitors to treat cancer - Google Patents

Silencing TGF-beta 1 and Cox2 using siRNAs delivered in combination with immune checkpoint inhibitors to treat cancer Download PDF

Info

Publication number
AU2019414427A1
AU2019414427A1 AU2019414427A AU2019414427A AU2019414427A1 AU 2019414427 A1 AU2019414427 A1 AU 2019414427A1 AU 2019414427 A AU2019414427 A AU 2019414427A AU 2019414427 A AU2019414427 A AU 2019414427A AU 2019414427 A1 AU2019414427 A1 AU 2019414427A1
Authority
AU
Australia
Prior art keywords
sirna
tgf
beta
cancer
cox2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019414427A
Other languages
English (en)
Inventor
David M. Evans
Patrick Y. Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirnaomics Inc
Original Assignee
Sirnaomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirnaomics Inc filed Critical Sirnaomics Inc
Publication of AU2019414427A1 publication Critical patent/AU2019414427A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99001—Prostaglandin-endoperoxide synthase (1.14.99.1), i.e. cyclooxygenase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2019414427A 2018-12-27 2019-12-24 Silencing TGF-beta 1 and Cox2 using siRNAs delivered in combination with immune checkpoint inhibitors to treat cancer Abandoned AU2019414427A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785647P 2018-12-27 2018-12-27
US62/785,647 2018-12-27
PCT/US2019/068499 WO2020139897A1 (en) 2018-12-27 2019-12-24 Silencing tgf-beta 1 and cox2 using sirnas delivered in combination with immune checkpoint inhibitors to treat cancer

Publications (1)

Publication Number Publication Date
AU2019414427A1 true AU2019414427A1 (en) 2021-07-22

Family

ID=71129448

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019414427A Abandoned AU2019414427A1 (en) 2018-12-27 2019-12-24 Silencing TGF-beta 1 and Cox2 using siRNAs delivered in combination with immune checkpoint inhibitors to treat cancer

Country Status (10)

Country Link
US (1) US20210324384A1 (https=)
EP (1) EP3902817A4 (https=)
JP (1) JP7588074B2 (https=)
KR (1) KR20220030203A (https=)
CN (1) CN114144423B (https=)
AU (1) AU2019414427A1 (https=)
BR (1) BR112021012715A2 (https=)
CA (1) CA3125285A1 (https=)
IL (1) IL284412A (https=)
WO (1) WO2020139897A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021061437A1 (en) * 2019-09-12 2021-04-01 Sirnaomics, Inc. CO-DELIVERY OF TGF-β SIRNA AND PDL1 SIRNA TO TREAT CANCER
JP2024506240A (ja) * 2021-01-21 2024-02-13 サーナオミクス インコーポレイテッド 皮膚がんの治療のための組成物および方法
CN115463148A (zh) * 2021-06-11 2022-12-13 圣诺生物医药技术(苏州)有限公司 一种用于治疗皮肤肿瘤的小干扰核酸药物组合物及制剂
CN115919888A (zh) * 2021-07-16 2023-04-07 圣诺生物医药技术(苏州)有限公司 一种用于治疗多种肿瘤的核酸干扰药物组合物
CA3225925A1 (en) * 2021-07-16 2023-01-19 Sirnaomics, Inc. Sirna-copolymer compositions and methods of use for treatment of liver cancer
WO2023086386A1 (en) * 2021-11-09 2023-05-19 Sirnaomics, Inc. Treatment of 2019-ncov using sirnas against tgfb1 and cox2
EP4437107A4 (en) * 2021-11-22 2025-04-23 Sirnaomics, Inc. Method for inducing remodeling of adipose tissue using RNAi therapeutics
CN116421616B (zh) * 2022-03-17 2025-08-12 圣诺生物医药技术(苏州)有限公司 一种核酸干扰药物组合物及用于治疗结直肠癌、胃癌、前列腺癌的药物
CN116983322B (zh) * 2022-09-15 2026-04-07 圣诺生物医药技术(苏州)有限公司 用于治疗肺癌、胰腺癌、肝癌和结直肠癌的小核酸干扰药物
EP4673542A1 (en) * 2023-03-01 2026-01-07 Philipps-Universität Marburg Plac8 antisense molecules used as a medicament
WO2025171164A1 (en) * 2024-02-07 2025-08-14 Board Of Regents, The University Of Texas System Gene signatures predictive of cancer cell response to immunomodulatory therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
WO2001047496A1 (en) 1999-12-29 2001-07-05 Mixson A James Histidine copolymer and methods for using same
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
AU2005218759B2 (en) 2004-02-27 2009-07-16 Antisense Pharma Gmbh Pharmaceutical composition
CN101060849A (zh) 2004-11-17 2007-10-24 巴尔的摩马里兰大学 作为有效的siRNA载体的高分支HK肽
JP2011504170A (ja) 2007-11-06 2011-02-03 サーナオミクス、インク． 皮膚の中で平癒している瘢痕のない損傷のためのマルチ目標とされたＲＮＡｉ治療学
WO2009104051A2 (en) * 2007-12-31 2009-08-27 Lu Patrick Y Combinational therapeutics for treatment of prostate cancer using epoxy encapsulated magnetic particles and rnai medicine
WO2009151539A1 (en) * 2008-05-24 2009-12-17 Sirnaomics, Inc. COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS
WO2011140285A2 (en) * 2010-05-04 2011-11-10 Sirnaomics, Inc. Combinations of tgfbeta and cox-2 inhibitors and methods for their therapeutic application
WO2018081726A2 (en) * 2016-10-30 2018-05-03 Sirnaomics, Inc. Pharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis
US20190290614A1 (en) * 2016-11-09 2019-09-26 Beth Israel Deaconess Medical Center, Inc. Methods for Reducing Recurrence of Tumors
CN110573166B (zh) * 2017-03-19 2023-08-22 圣诺生物医药技术(苏州)有限公司 用于癌症治疗的吉西他滨衍生物

Also Published As

Publication number Publication date
IL284412A (en) 2021-08-31
BR112021012715A2 (pt) 2021-09-21
KR20220030203A (ko) 2022-03-10
CN114144423B (zh) 2025-04-04
JP2022515868A (ja) 2022-02-22
CN114144423A (zh) 2022-03-04
CA3125285A1 (en) 2020-07-02
JP7588074B2 (ja) 2024-11-21
EP3902817A4 (en) 2022-08-03
EP3902817A1 (en) 2021-11-03
WO2020139897A1 (en) 2020-07-02
US20210324384A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
JP7588074B2 (ja) がんを治療するために、免疫チェックポイント阻害剤と組み合わせて送達されるｓｉＲＮＡを使用したＴＧＦ－ベータ１およびＣｏｘ２のサイレンシング
Strand et al. Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles
Won et al. Signal transducer and activator of transcription 3‐mediated CD133 up‐regulation contributes to promotion of hepatocellular carcinoma
JP5671487B2 (ja) 放射線治療の有効性を増強するためのｍｅｔ阻害剤
Shao et al. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors
Nomura et al. β2-Microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP–responsive element-binding protein, and vascular endothelial growth factor Axis
Kwan et al. Macrophages mediate the antitumor effects of the oncolytic virus HSV1716 in mammary tumors
US12060619B2 (en) Treatment of angiogenesis disorders
Fu et al. Combination foretinib and anti-PD-1 antibody immunotherapy for colorectal carcinoma
JP2022515868A5 (https=)
An et al. Locally Trapping the C‐C Chemokine Receptor Type 7 by Gene Delivery Nanoparticle Inhibits Lymphatic Metastasis Prior to Tumor Resection
EP2421888B1 (en) CLEVER-1 Receptor Antagonists for blocking immune-inhibitory type 2 macrophages.
Lee et al. Tissue transglutaminase activates cancer-associated fibroblasts and contributes to gemcitabine resistance in pancreatic cancer
JP2021514190A (ja) コード化リボ核酸の器官保護発現および調節のための組成物および方法
JP2025118790A (ja) Ｆｍｒｐ及び癌治療
Uchida et al. Glypican-1-targeted antibody–drug conjugate inhibits the growth of glypican-1-positive glioblastoma
US8740762B2 (en) Specific inhibition of cPLA2 enhances the efficacy of radiotherapy
CN111249477A (zh) 一种基于基因干扰载体和铁纳米粒子用于杀灭癌细胞的组合物及其应用
Thomas et al. Knock-down of calcitonin receptor expression induces apoptosis and growth arrest of prostate cancer cells
AU2014331728A1 (en) Methods and compositions for regulatory T-cell ablation
RU2797510C2 (ru) САЙЛЕНСИНГ TGF-БЕТА 1 И Cox-2 С ИСПОЛЬЗОВАНИЕМ миРНК, ДОСТАВЛЯЕМОЙ В ПОЛИПЕПТИДНОЙ НАНОЧАСТИЦЕ, В ОТДЕЛЬНОСТИ И В КОМБИНАЦИИ С ИНГИБИТОРАМИ ИММУННЫХ КОНТРОЛЬНЫХ ТОЧЕК ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ
US20100310579A1 (en) Method for inhibiting angiogenesis or for treatment of cancer
JP2024525847A (ja) ｓｉＲＮＡ共重合体組成物および肝臓がんの治療のための使用の方法
US20180230466A1 (en) Methods for treating tumors
Lin et al. Targeting ZDHHC9 enhances anti-PD-L1 immunotherapy efficacy by reprogramming the tumour microenvironment

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application